Skip to main content
SpringerLink
Log in

Therapy of Alzheimer’s Dementia

Past, Present, and Future

  • Chapter
Recent Advances in Geriatrics

  • 82 Accesses

Abstract

Alzheimer’s dementia, one of the most important causes of severe disability in the elderly, fourth cause of death in adults in Western Countries (Bush et al., 1994), represents a dramatic health problem, especially for social and economic implications, whose risk factors are, at present, only age (Herbert et al., 1995), lower education (Ganguli et al., 1991), ApoE genotype (Feskens et al., 1994; Locke et al, 1995), and, possibly, head trauma (Fratiglioni, 1993). The issue “Alzheimer” has been efficaceously synthetized by Khachaturian and collegues with the formula P AD = N × D × C, where N represents the total number of affected individuals, D the lenght in time of the disease, C the costs of diagnosis, treatment and assistance (Khachaturian et al., 1994). The solution of such a problem requests therefore an articulate approach, able to influence each of the above factors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agnoli A, Fabbrini G, Fioravanti M, Martucci N. CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study. Eur. Neuropsychopharmacol. 2:31–35, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Amenta D, Ferrante F, Franch F, Amenta F. Effects of long-term Hydergine administration on lipofuscin accumulation in senescent rat brain. Gerontologist 34:250–256, 1988.

    Article  CAS  Google Scholar 

  • Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal antiinflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology, 45: 1441, 1995.

    Article  PubMed  CAS  Google Scholar 

  • Augustinsson LE, Blennow K, Blomstrand C, et al. Intracerebroventricular administration of GM1 ganglioside to presenile Alzheimer patients. Dementia (in press).

    Google Scholar 

  • Banfi S, Dorigotti L. Experimental behavioural studies with oxiracetam on different types of chronic cerebral impairment. Clin. Neuropharmacol. 7 (Suppl. 1):768–769, 1984.

    Google Scholar 

  • Bartus RT, Dean RL, Beer B. Cholinergic precursor therapy for geriatric cognition: its past, its present and a question of its future. In: Nutrition in gerontology, Orsy et al. (eds.) Raven Press, New York, pp. 191–225, 1984.

    Google Scholar 

  • Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory disfunction. Science 217:408–417, 1982.

    Article  PubMed  CAS  Google Scholar 

  • Beal M.F. Does impairment of energy matabolism result in excitotoxic neuronal death in neurodegenerative illnesses?. Ann. Neurol. 31: 119–130, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Beal MF, Mazurek MF, Tran VT, et al. Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer’s disease. Science 229:289–291, 1985.

    Article  PubMed  CAS  Google Scholar 

  • Becker R, Moriearty P and Unni L: The second generation of Cholinesterase inhibitors: clinical and pharmacological effects. In: Cholinergic Basis for Alzheimer Therapy, Becker RE and Giacobini E, eds. Boston: Birkhauser, pp 263–296, 1991.

    Google Scholar 

  • Benesova O, Kristofikova Y, Tejkalova H. Experimental study of long-term administration of Cholinesterase inhibitors in aging rats. Homeostasis 33:170–172, 1991b.

    PubMed  CAS  Google Scholar 

  • Bergamasco B, Villardita C, and Coppi R: Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial. Arch Gerontol Geriatr, 15: 271–2378, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Berzaghi M, Cooper J, Castren E, Zafra F, Sofroniew M, Thoenen H and Lindholm D: Cholinergic regulation of brain-derived neurotrophic factor and nerve growth factor but not neurotrophin-3 mRNA levels in the developing rat hippocampus. J Neurosci 13: 3818–3826, 1993.

    CAS  Google Scholar 

  • Bissette G, Myers B. Somatostatin in Alzheimer’s disease and depression. Life Sci. 51:1389–1410, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Bormann J: Memantine is a potent bloker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166:591–594, 1989.

    Article  PubMed  CAS  Google Scholar 

  • Bowen DM, Allen SJ, Benton JS, et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer’s disease. J. Neurochem. 41:226–272, 1983.

    Google Scholar 

  • Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99:459–496, 1976.

    Article  PubMed  CAS  Google Scholar 

  • Brandeis R, Dachir S, Sapir M, Levy A, Fisher A. Reversal of age-related cognitive impairment by an M1 cholinergic agonist, AF102B. Pharmacol. Biochem. Behav. 36:89–95, 1990.

    Article  PubMed  CAS  Google Scholar 

  • Bush TL, Miller SR, Criqui MN, et al. Risk factors for morbidity and mortality in older population: an epidemiological approach. In: Hazzard WR. Bierman EL, Blass JP, et al., editors: Principles of geriatric medicine and gerontology. New York, McGraw Hill, 153–166, 1994.

    Google Scholar 

  • Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE and Greengard P: Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad SCI USA 89: 10075–10078, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Canal N, Franceschi M and the Italian Eptastigmine Investigators: Eptastigmine (MF-201). A double-blind, placebo-controlled, clinical trial in Alzheimer disease patients. In: Alzheimer Disease: Therapeutic Strategies, eds E. Giacobini and R. Becker, Birkhäusser Boston, pp 108-112, 1994.

    Google Scholar 

  • Canal N, Imbimbo B, for the Eptastigmine Study Group. Clinical trial and therapeutics: relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer’s disease. Clin. Pharmacol. Ther. 60: 218–228, 1996.

    Article  PubMed  CAS  Google Scholar 

  • Carney JM, Starke-Reed PE, Oliver CN, Landum RW, Cheng MS, Wu JF, and Floyd R. Proc. Natl. Acad. Sci. U.S.A. 88, 3633–3636, 1991.

    Article  PubMed  CAS  Google Scholar 

  • Cervera-Pierot P, Hirsch EC, Javoz-Agid F, et al. Hippocampal and parahippocampal somatostatin 28 and neuropeptide Y containing neurons in Alzheimer’s disease. Dementia 3:282–298, 1992.

    Google Scholar 

  • Collins RC: elective vulnerability of brain: new insights from the excitatory synapse Metab. Brain Dis. 1: 231–240, 1986

    Article  CAS  Google Scholar 

  • Coyle JT, Price DL, De Long MR. Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science 219:1184–1190, 1983.

    Article  PubMed  CAS  Google Scholar 

  • Cuadra G, Summeers K and Giacomini E: Cholinesterase inhibitors effects on neurotransmitters in rat cortex in vivo. J Pharmacol Exptl Therapeutics 270, 1994 (in press).

    Google Scholar 

  • Cucinotta D, Passeri M, Ventura S, et al. Mulcenter clinical placebo-controlled study with acetyl-l-carnitine(LAC) in the treatment of mildly demented elderly patients. Drug Dev. Res. 14:213–216, 1988.

    Article  Google Scholar 

  • Cummings J.L., Victoroff J. Noncognitive neuropsychiatrie syndromes in Alzheimer’s disease. Neuropsychiatry Neuropsychol. Behavioral Neurol. 2: 140, 1990.

    Google Scholar 

  • Davies P. Theoretical treatment possibilities for dementia of the Alzheimer’s type. The cholinergic hypothesis. In: Strategies for the development of an effective treatment for senile dementia, Crook & Gershon (eds.) M. Powley Ass., Madison, pp. 19-34, 1981.

    Google Scholar 

  • Davies P, Katzman R, Terry RD. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer’s disease and Alzheimer senile dementia. Nature 288:279–280, 1980.

    Article  PubMed  CAS  Google Scholar 

  • Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet ii: 1403, 1976.

    Article  Google Scholar 

  • Davis KL, Thal LJ, Gamzu ER et al.: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s disease. N Engl J Med 327: 1253–1259, 1992.

    Article  PubMed  CAS  Google Scholar 

  • De Feudis FV. Central cholinergic system, cholinergic drugs and Alzheimer’s disease-an overview. Drugs Today 24:473–490, 1988.

    Google Scholar 

  • De Jong R, Osterlund OW, Roy GW: Measurement of quality of life change in patients with Alzheimer’s disease. Clin. Ther. 11:545, 1989.

    Google Scholar 

  • De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW. Reciprocal changes in corticotropin-relaising factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer’s disease. Nature 319:593–595, 1986.

    Article  PubMed  Google Scholar 

  • De Wied D. Effects of peptide hormones on behaviour. In: Frontiers in neuroendocrinology, Oxford University Press, London, pp. 97–140, 1989.

    Google Scholar 

  • Dolezal V, Tucek S. Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose to the synthesis of acetylcholine in rat brain slices. J. Neurochem. 36:1323–1330, 1981.

    Article  PubMed  CAS  Google Scholar 

  • Drachman DA, Glosser G. Pharmacologic strategies in aging and dementia: the cholinergic hypothesis. In: Strategies for the development of an effective treatment for senile dementia, Crook & Gershon (eds.) M. Powley Ass., Madison, pp. 35–51, 1981.

    Google Scholar 

  • Dreyfus CF. Effects of nerve growth factor on cholinergic brain neurons. Trends Pharmacol. Sci. 10:145–149, 1989.

    Article  PubMed  CAS  Google Scholar 

  • Duara R, Grady C, Haxby J, Sundaram M, Cutler NR, Heston L, Moore A, Schlageter N, Larson S, Rapoport SI. Positron emission tomography in Alzheimer’s disease. Neurology 36: 879–887, 1986.

    Article  PubMed  CAS  Google Scholar 

  • Dunne MP, Hartley LR. Scopolamine and the control of attention in humans. Psychopharmacology 89: 94–97, 1986.

    Article  PubMed  CAS  Google Scholar 

  • Dyrks T, Dyrks E, Hartmann T, et al. Amyloidogenicity of β-A4 and βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J Biol Chem, 267: 18210–17, 1992.

    PubMed  CAS  Google Scholar 

  • Dyrks T, Dyrks E, Masters CL, et al. Amyloidogenicity of rodent and human βA4 sequences. FEBS Lett. 324: 231–236, 1993.

    Article  PubMed  CAS  Google Scholar 

  • Eagger SA, Levy R, Sahakian BJ: Tacrine in Alzheimer’s disease. Lancet 337: 989–992, 1991.

    Article  PubMed  CAS  Google Scholar 

  • Eagger SA, Richards M, Levy R: Long-term effects of tacrine in Alzheimers disease: an open study. Int. J. Geriatr. Psychiatry. 9: 643–647, 1994.

    Article  Google Scholar 

  • Enz A, Amstutz R, Boddeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. Progr. Brain Res., 98: 431–438, 1993.

    Article  CAS  Google Scholar 

  • Farlow M, Gracon SI, Hershey LA et al.: A controlled trial of tacrine in Alzheimer’s disease. JAMA 268: 2523–2529, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Favit A, Nicoletti F, Scapagnini U, et al. Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration. J. Cereb. Blood Flow Metab. 12. 638–645, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Feskens EJM, Havekes LM, Kalmijn S, et al. Apolipoprotein E4 allele and cognitive decline in elderly men. Br. Med. J. 309: 1202–1206, 1994.

    Article  CAS  Google Scholar 

  • Fillit H, Weinreb H, Cholst I. Observations in a preliminary open trial of estradiol therapy for senile dementia (Alzheimer’s type). Psychoneuroendocrinology 2: 337–345, 1986.

    Article  Google Scholar 

  • Fisher A, Brandeis R, Karton I, et al. AF102B: rational treatment strategy for Alzheimer’s disease: recent advances. In: Advances in neurology, Wurtman et al. (eds.) Vol. 51 Alzheimer’s Disease, Raven Press, New York, pp. 257–259, 1990.

    Google Scholar 

  • Fratiglioni L. Epidemiology of Alzheimer’s disease: issues of etiology and validity. Acta Neurol. Scand. 87: 1–912, 1993.

    Article  Google Scholar 

  • Gabuzda DH, Busciglio J, Chen LB, Matsudaira P, Yankner BA. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 6: 13623–13628, 1994.

    Google Scholar 

  • Ganguli M, Ratcliff G, Huff FJ, et al. Effects of age, gender, andeducation on cognitive tests in a rural elderly commuity sample: norms from the Monongahela Valley Independent Elders Survey (MoVIES). Neuroepidemiology 10: 42–52, 1991.

    Article  PubMed  CAS  Google Scholar 

  • Gelowitz DL, Richardson JS, Wishart PH, Yu PH, Lai CT. Chronic L-deprenyl or D-amphetamine: equal cognitive enhancement unequal MAO inhibition. Pharmacol. Biochem. Behav. 47:41–45, 1994.

    Article  PubMed  CAS  Google Scholar 

  • Goodnick P, Gershon S. Chemotherapy of cognitive disorders in geriatric subjects. J. Clin. Psychiatry 45:196–209, 1984.

    PubMed  CAS  Google Scholar 

  • Görtelmeyer R, Erbler H: Mementine in the treatment of mild to moderate dementia syndrome: a double-blind placebo controlled styudy. Arzneimittel-Forschung. 42: 904–913, 1992.

    PubMed  Google Scholar 

  • Gottfries CG. Neurochemical aspects of dementia disorders. Dementia 1:56–64, 1990.

    Google Scholar 

  • Greene JG, Porter RHP, Eller RV, et al. Inhibition of succinate dehydrogenase by malonic acid produces an “excitotoxic” lesion in rat striatum. J. Neurochem. 61: 1151–1154, 1993.

    Article  PubMed  CAS  Google Scholar 

  • Gutteridge JMC, Quinlan GJ, Clark I, Halliwel B: Aluminum salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochimica Biophysica Acta. 835: 441–447, 1985.

    Article  CAS  Google Scholar 

  • Hagan JJ, Morris RGM. The cholinergic hypothesis of memory: a review of animal experiments. In: Iversen LL, Iversen SD, Snyder SH (Eds.), Handbook of Psychopharmacology, Plenum Press, New York, 237–305, 1988.

    Chapter  Google Scholar 

  • Hajimohammadreza I, Brammer M. Brain membrane fluidity and lipid peroxidation in Alzheimer’s disease. Neurosci Lett, 112: 333–7, 1990.

    Article  PubMed  CAS  Google Scholar 

  • Hall ED. Cerebral ischemia, free radicals and antioxidant protection. Biochem Soc Trans, 21: 334–9, 1993.

    PubMed  CAS  Google Scholar 

  • Hallak M, Giacobini E. Physostigmine, tacrine and metrifonate: the effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 28:199–206, 1989.

    Article  PubMed  CAS  Google Scholar 

  • Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11:298–300, 1956.

    Article  PubMed  CAS  Google Scholar 

  • Harman D. Free radical involvement in aging: pathophysiology and therapeutic implications. Drugs & Aging 3:60–80, 1993.

    Article  CAS  Google Scholar 

  • Haxby JV, Grady CL, Duara R, Sclageter NL, Berg G, Rapoport SI. Neocortical metabolic abnormalites precede nonmemory cognitive deficits in early Alzheimer type dementia. Arch. Neurol. 43: 882–885, 1986.

    Article  PubMed  CAS  Google Scholar 

  • Hefti F, Hartikka J, Knusel B. Function of neurotrophic factors in the adult and aging brain and their possible use in the treatment of neurodegenerative diseases. Neurobiol. Aging 10:515–533, 1989.

    Article  PubMed  CAS  Google Scholar 

  • Herbert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer’s disease in a community population. JAMA 273: 1354–1359, 1995.

    Article  Google Scholar 

  • Herrmann WM, Stephan K, Gaede K, Apeceche M: Multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infatct dementia. AADE Ed J. 8:9–17, 1997.

    CAS  Google Scholar 

  • Hiatt L.G. Environmental design and mentally impaired older people. In: Haltman H.J., (Ed.) Alzheimer’s disease and dementia, New York, Plenum Press; 214, 1986.

    Google Scholar 

  • Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate in the central nervous system-senile dementia (Alzheimer’s type). J. Steroid Biochem. 34: 521–525, 1989.

    Article  PubMed  CAS  Google Scholar 

  • Imbimbo PB, Lucchelli PE. A pharmacodynamic strategy to optimize the clinical response to eptastigmine (MF-201). In: Alzheimer disease: therapeutic strategies, E. Giacobini, R. Becker, Birkhäuser, Boston, pp. 103–107, 1994.

    Chapter  Google Scholar 

  • Iqbal K, Grundke-Iqbal I, Smith AJ, et al. Identification and localization of a tau peptide to paired helical filaments of Alzheimer’s disease. Proc Natl Acad Sci USA, 86: 5646–50, 1989.

    Article  PubMed  CAS  Google Scholar 

  • Jansen KLR. Is treating memory impairment in Alzheimer’s disease an objective? Trends Neurosci. 11:210, 1988.

    Article  PubMed  CAS  Google Scholar 

  • Janson AM and Moller A: Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesiodiencephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 57(4): 931–941, 1993.

    Article  PubMed  CAS  Google Scholar 

  • Johns CA, Haroutunian V, Greenwald BS, et al. Development of cholinergic drugs for the treatment of Alzheimer’s disease. Drug Dev. Res. 5:77–96, 1985.

    Article  Google Scholar 

  • Kawas C, Resnick S, Morrison A et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: The Baltimore Longitudinal Study of Aging. Neurology, 48: 1517–1521, 1997.

    Article  PubMed  CAS  Google Scholar 

  • Khachaturian Z.S., Phelps C.H., Buckholtz N.S.: The prospect of developing treatments for Alzheimer disease. In: Alzheimer Disease, edited by Terry R.D., Katzman R., Bick K.L., Raven Press, New York, 445–457, 1994.

    Google Scholar 

  • Kirk RC, White KG, McNaughton N. Low dose of scopolamine affects discriminability but not rate of forgetting in delayed conditional discrimination. Psychopharmacology 96: 541–546, 1988.

    Article  PubMed  CAS  Google Scholar 

  • Knapp M.J., Knopman D.S., Solomon P.R., Pendlebury W.W., Davis C.S., Gracon S.I. for the Tacrine Study Group: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 27, 985, 1996.

    Google Scholar 

  • Knapp MJ, Knopman DS, Solomon PR et al.: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 271: 985–991, 1994.

    Article  PubMed  CAS  Google Scholar 

  • Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech. Ageing Dev. 46:237–262, 1988.

    Article  PubMed  CAS  Google Scholar 

  • Knopman D.D., Sawyer-DeMaris S. Practical approach to managing behavioural problems in dementia patients. Geriatrics 45: 27, 1990.

    PubMed  CAS  Google Scholar 

  • Köberle S, Spiegel R. A long-term study with co-dergocrine mesylate (Hydergine) in healthy pensioners. Gerontology 30 237–262, 1984.

    Google Scholar 

  • Koliatsos VE, Clatterbuck RE, Nauta HJW, et al. Human nerve growth factor prevents degeneration of basal fore-brain cholinergic neurons in primates. Ann. Neurol. 30:831–840, 1991.

    Article  PubMed  CAS  Google Scholar 

  • Kornhuber J, Bormann J, Retz W, Huber M, Riederer P: Mementine displaces [H] MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Phatrmacol. 166: 589–590, 1989.

    Article  CAS  Google Scholar 

  • Koroshetz W, Jenkins B, Rosen B, et al. Ubiquinone lowers occipital lactate levels in patients with Huntington’s disease. Neurology 43 (suppl. 2): A334, 1993.

    Google Scholar 

  • Lindfors N, Ernfors P, Falkenberg T and Persson H: Septal cholinergic afferents regulate expression of brain-derived neurotrophic factor and beta-nerve growth factor mRNA in rat hippocampus. Exp Brain Res 88: 78–90, 1992.

    Article  Google Scholar 

  • Locke PA, Conneally PM, Tanzi RE, et al. Apolipoprotein E4 allele and Alzheimer’s disease: Examination of allelic association and effect on age at onset in both early-and and late-onset cases. Genet. Epidemiol. 12: 83–92, 1995.

    Article  PubMed  CAS  Google Scholar 

  • Mace N., Rabins P. The 36-Hour Day. Revised Edition, The John Hopkins University Press, 1991.

    Google Scholar 

  • Marigliano V, Abate G, Barbagallo-Sangiorgi G et al.: Randomized, double-blind, placebo-controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia., Arch Gerontol Geriatr 15: 239–248, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Markowska AL, Ingram DK, Barnes CA, et al. Acetyl-l-carnitine: I. Effects on mortality, pathology and sensory-motor performance in aging rats. Neurobiol. Aging 11:491–498, 1990.

    Article  PubMed  CAS  Google Scholar 

  • Markstein R. Pharmacological approaches in the treatment of senile dementia. Eur. Neurol. 29 (Suppl.):33–41, 1989.

    Article  PubMed  Google Scholar 

  • McGeer PL, Harada N, Kimura H, et al. Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia, 3: 146, 1992.

    Google Scholar 

  • McGeer PL, McGeer EG, Rogers J, et al. Antiinflammatory drugs and Alzheimer’s disease (letter). Lancet, 335: 1037, 1990.

    Article  PubMed  CAS  Google Scholar 

  • McLachlan DR, Kruck TPA, Smith WL. Aluminum chelation therapy of Alwheimer’s disease. In: Giacobini E, Beker R, editors. Alzheimer disease: therapeutic strategies. Boston: Birkhauser, 328–33, 1994.

    Chapter  Google Scholar 

  • McLachlan DR, Smith WL, Kruck TPA. Desferrioxamine and Alzheimer’s disease: video home behavior assessment of clinical course and measures of brain aluminum. Ther Drug Monit. 15:602–607, 1993.

    Article  PubMed  CAS  Google Scholar 

  • Mecocci P, MacGarvey U., Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol, 36: 747–51, 1994.

    Article  PubMed  CAS  Google Scholar 

  • Meyer-Ruge W. Effects of prolonged co-dergocrine mesylate (Hydergine) treatment on local cerebral glucose uptake in aged Fisher 344 rats. Arch. Gerontol. Geriatr. 5:65–67, 1986.

    Article  Google Scholar 

  • Milan F, Nunzi MG, Guidolin D. Age related loss of dendritic spines in rat hippocampus: effects of phosphatidyl-serine administration. In: Senile dementias: early detection, A. Bes, J. Cahn, R. Cahn (eds.) John Libbey Eurotext, p. 408, 1986.

    Google Scholar 

  • Minthon L, Edvinsson L, Ekman R, Gustafson L. Reduced lumbar cerebrospinal fluid somatostatin levels in Alzheimer’s disease and dementia with frontotemporal degeneration. Dementia 2:273–277, 1991.

    Google Scholar 

  • Moore MJ and Clipp EC: Alzheimer’s disease and caregiver time. Lancet 343(8891): 239–240, 1994.

    Article  PubMed  CAS  Google Scholar 

  • Morgan DG, Finch CE. Neurotransmitter receptors in Alzheimer’s disease and nonpathological aging. In: Molecular neuropathology of aging, Banbury Report 27, Cold Spring Harbor Laboratory, pp. 21-35, 1988.

    Google Scholar 

  • Nappi G, Bono G, Merlo P et al.: Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly. Arch Gerontol Geriatr 15: 261–269, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Nitsch RM, Farber SA, Growdon JH and Wurtman RJ: Release of amyloid β-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc Natl Acad Sci USA 90: 5191–5193, 1993.

    Article  PubMed  CAS  Google Scholar 

  • Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebr. Brain Metab. Rev. 4:303–328, 1992.

    CAS  Google Scholar 

  • Nordberg A, Winblad B. Reduced number of 3h-nicotine and 3H acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72:115–119, 1986.

    Article  PubMed  CAS  Google Scholar 

  • Novelli A, Reilly JA, Lysko PG, et al. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451: 205–212, 1988.

    Article  PubMed  CAS  Google Scholar 

  • Ohkura T., Isse K., Akazawa K., et al. Evaluation of estrogen treatment in female patients with dementia of Alzheimer’s type. Endocrine J. 41: 361, 1994.

    Article  CAS  Google Scholar 

  • Ohkura T., Isse K., Akazawa K., et al. Long-term estrogen replacement therapy in female patients with Alzheimer’s type dementia: seven case reports. Dementia 6: 99, 1995.

    PubMed  CAS  Google Scholar 

  • Olson L, Nordberg A, von Holst H., et al. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG and verbal episodic memory in an Alzheimer patient (case report). J. Neural Transm. 4:79–95, 1992.

    Article  CAS  Google Scholar 

  • Oreland L, Gottfries CG. Platelet and brain monoamine oxidase in aging and in dementia od Alzheimer’s type. Prog. Neuropsychopharmacol. Biol. Psychiatry 10:533–540, 1986.

    Article  PubMed  CAS  Google Scholar 

  • Papasozomenos S Ch, and Su Y. Rapid dephosphorylation of τ in heat-shocked fetal rat cerebral expiants: prevention and hyperphosphorylation by inhibitors of protein phosphatases PP1 and PP2A. J Neurochem, 65: 396–406, 1995.

    Article  PubMed  CAS  Google Scholar 

  • Pappolla MA, Omar RA, Kim KS, et al. Immunohistochemical evidence of antioxidant stress in Alzheimer’s disease. Am. J. Pathol 140: 621–628, 1992.

    PubMed  CAS  Google Scholar 

  • Parker WD Jr, Parks J, Filley CM, Kleinschmidt-DeMasters BK. Electron transport chain defects in Alzheimer’s disease brain. Neurology 44: 1090–1096, 1994.

    Article  PubMed  Google Scholar 

  • Parnetti L, Ambrosoli L, Abate G, et al. Posatirelin for the treatment of late-onset Alzheimer’s disease: a double-blind multicentre study vs citicoline and ascorbic acid. Acta Neurol. Scand. (in press).

    Google Scholar 

  • Parnetti L., Gaiti A., Mecocci P., Cadini D., Senin U. Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur. J. Clin. Pharmacol. 42: 89–93, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Parnetti L, Senin U, Carosi M, Baasch H, and The Nimodipine Study Group. Mental deterioration in old age: results of two multicenter, clinical trials with nimodipine. Clin. Ther. 15:394–406, 1993.

    PubMed  CAS  Google Scholar 

  • Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormities in senile dementia. J. Neurol. Sci. 34:247–265, 1977.

    Article  PubMed  CAS  Google Scholar 

  • Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 2:1457–1459, 1978.

    Article  PubMed  CAS  Google Scholar 

  • Piccinin GL, Finali G, Piccirilli M. Neuropsychical effects of 1-deprenyl in Alzheimer’s type dementia. Clin. Neuropharmacol. 13:147–163, 1990.

    Article  PubMed  CAS  Google Scholar 

  • Pomara N, Singh R, Deptula D, et al: Glutamate and other CSF amino acids in Alzheimer’s disease. Am. J. Psychiatry. 149:251–254, 1992.

    PubMed  CAS  Google Scholar 

  • Rich JB, Rasmusson DX, Folstein MF et al. Nonsteroidal antiinflammatory drugs in Alzheimer’s disease. Neurology, 45: 51, 1995.

    Article  PubMed  CAS  Google Scholar 

  • Richardson JS, Kumar U, Kala SV, et al. In vitro evidence for the use of antioxidants in Alzheimer’s dissease. In: Giacobini E, Becker R, editors. Alzheimer Disease: Therapeutic Strategies. Birkhäusser Boston, 334-9, 1994.

    Google Scholar 

  • Robinson D, Friedman L, Marcus R, et al. Estrogen replacement therapy and memory in older women. J. Am. Geriatr. Soc. 42: 919–922, 1994.

    PubMed  CAS  Google Scholar 

  • Rogers S.L., Friedhoff L.T. and the Donepezil Study Group: The efficacy and safety of Donepezil in patients with Alzheimer’s disease: results of a US multicentre randomized, double-blind, placebo-controlled trial. Dementia, 7: 293, 1996.

    PubMed  CAS  Google Scholar 

  • Rossor MN, Emson PC, Mountjoy CQ, Roth SM, Iversen LL. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type. Neurosci. Lett. 20:373, 1980.

    Article  PubMed  CAS  Google Scholar 

  • Saletu B, Paulus E, Linzmayer L, Anderer P: Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo controlled, clinical and EEG/ERP mapping study. Folha Med. 113, 103, 1996.

    Google Scholar 

  • Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV: Grunberger J, Wicke L, Neuhold A, Podreka I: Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo controlled, clinical and EEG/ERP mapping study. Psychopharmacology, 117: 385–395., 1995.

    Article  PubMed  CAS  Google Scholar 

  • Sano M, Ernesto C, Thomas RG, et al. A controlled trial of Selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med, 336: 1216–1222, 1997.

    Article  PubMed  CAS  Google Scholar 

  • Saraiva AA, Borges MM, Madeira MD, Tavares MA, Paula-Barbosa MM. Mitochondrial abnormalities in cortical dendrites from patients with Alzheimer’s disease. J. Submicrosc. Cytol 17: 459–464, 1985.

    PubMed  CAS  Google Scholar 

  • Sarter M, Schneider HH, Stephens DN. Treatment strategies for senile dementia: antagonist beta carbolines. Trends Neurosci. 11:13–17, 1988.

    Article  PubMed  CAS  Google Scholar 

  • Schmage N, Bergener M. Global rating, symptoms, behavior and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes. Int. Psychogeriatr. 4 (suppl. 1):89–99, 1992.

    PubMed  Google Scholar 

  • Schulz JB, Henshaw DR, Jenkins BG, et al. 3-acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. J. Cereb. Blood Flow Metab. 14: 1024–1029, 1994.

    Article  PubMed  CAS  Google Scholar 

  • Schwartz RD, Coughenour LL, Davis RE, et al. Novel muscarinic agonists for the treatment of Alzheimer’s disease. In: Cholinergic basis for Alzheimer therapy, Becker & Giacobini (eds.), Birkhäuser, New York, pp. 347-353, 1991a.

    Google Scholar 

  • Schwartz RD, Davis RE, Gracon S, et al. New generation tacrine. Neurobiol. Aging 12:185–187, 1991b.

    Article  Google Scholar 

  • Senin U, Abate G, Fieschi C, Gori G, Guala A, Marini G, Villardita C, Parnetti L: Aniracetam (Ro 13-5057) in the treatment of senile dementia of Alzheimer type (SDAT): Results of a placebo controlled multicenter clinical study. Eur Neuropsychopharmacology 1: 511–517, 1991.

    Article  CAS  Google Scholar 

  • Senin U, Cherubini A, Mecocci P. I farmaci per i disturbi cognitivi: fra presente e futuro. Giorn. Geront., 1996 (in press).

    Google Scholar 

  • Senin U, Parnetti L, Barbagallo-Sangiorgi G et al.: Idebenone in senile dementia of Alzheimer type: A multicentre study. Arch Gerontol Geriatr 15: 249–260, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell P, Mirra SS, Beal MF, Yang C-C, Gearing M, Salvo R, Watts R, Juncos JL, Hanson LA, Crain BJ, Fayad M, Wallace DW. Mitochondrial DNA mutations associated with Alzheimer’s and Parkinson’s disease. Genomics 17: 171–184, 1993.

    Article  PubMed  CAS  Google Scholar 

  • Shurtleff D, Raslear TG, Genovese RF, Simmons L. Perceptual bisection in rats: the effects of physostigmine, scopolamine and pirenzipine. Physiol. Behav. 51: 381–390, 1992.

    Article  PubMed  CAS  Google Scholar 

  • Siegfred K: The pharmacodynamics of velnacrine: results and conclusion from clinical studies in ealthy subjects and patients with Alzheimer’s disease. In: The Management of Alzheimer’s disease, Wilcock GK, ed. Wrightson Biomedical Publishing Ltd., pp. 189-201, 1993.

    Google Scholar 

  • Siesjo BK. Historical overview: calcium, ischemia and death of brain cells. Ann. N Y Acad. Sci. 522:638–661, 1988.

    Article  PubMed  CAS  Google Scholar 

  • Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J. Neuro-chem. 40:503–509, 1983.

    CAS  Google Scholar 

  • Sims NR, Bowen DM, Neary D, Davison AN. Metabolic processes in Alzheimer’s disease: Adenine nucleotide content and production of 14CO2 from [U-14C] glucose in vitro in human neocortex. J. Neurochem. 41: 1329–1334, 1993.

    Article  Google Scholar 

  • Sjak-shie NN, Burks JN and Meyer EM: Long-term actions on nicotinic receptor stimulation in nucleus basalis lesioned rats: blockade of trans-synaptic cell loss. In: Advances in Behavioral Biology, Vol 2, Nagatsu T, Fisher A and yoshida M, eds. New York: Plenum Press, pp 471–475, 1990.

    Google Scholar 

  • Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc Natl Acad Sci USA, 88: 10540–43, 1991.

    Article  PubMed  CAS  Google Scholar 

  • Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Hungtington and Alzheimer brain. Ann. Neurol. 13: 72–78, 1993.

    Article  Google Scholar 

  • Southorn P, Powis G. Free radicals in medicine: I. Chemical nature and biologic reactions. Mayo Clin. Proc. 63:381–389, 1988a.

    Article  PubMed  CAS  Google Scholar 

  • Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M., Frattura L., Tiraboschi P., Comelli M., Senin U., Longo A., Petrini A., Brambilla G., Belloni A., Negri C., Cavazzuti F., Saisi A., Calogero P., parma E., Stramba-Badiale M., Vitali S., Andreoni G., Inzoli M.R., Santus G., Caregnato R., Peruzza M., Favareytto M., Bozeglav C., Alberoni M., De Leo D., Serraiotto L., Baiocchi A., Scoccia S., Culotta P., Ieracitano D.: Long-term acetyl-L-carnitine treatment in Alzheimer’s disease. Neurology 41, 1726, 1991.

    Article  PubMed  CAS  Google Scholar 

  • Spignoli G, Pedata F, Giovannelli L, Banfi S, Moroni F, Pepeu G. Effects of oxiracetam and piracetam on central cholinergic mechanisms and active-avoidance acquisition. Clin. Neuropharmacol. 9 (suppl. 3):39–47, 1986.

    Google Scholar 

  • Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS and Roses AD: Apolipo-protein E: High avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90: 1977–1981, 1993.

    Article  PubMed  CAS  Google Scholar 

  • Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer’s cortex show increased peroxidation in vitro. J Neurochem, 55: 342–5, 1990.

    Article  PubMed  CAS  Google Scholar 

  • Summers KL, Cuadra G, Naritoku D and Giacobini E: Effects of nicotine levels on acetylcholine and biogenic amines in rat cortex. Drug Dev Res 31: 108–119, 1994.

    Article  CAS  Google Scholar 

  • Summers WK, Majovski LV, Marsh GM et al.: Orla tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 315: 1241–1245, 1986.

    Article  PubMed  CAS  Google Scholar 

  • Sunderland T, Rubinow DR, Tariot PN, et al. CSF somatostatin in patients with Alzheimer’s disease, older depressed patients and age-matched controls. Am. J. Psychiatry 144:1313–1316, 1987.

    PubMed  CAS  Google Scholar 

  • Tariot PN, Cohen RM, Sunderland T., et al. L-deprenyl in Alzheimer’s disease: preliminary evidence for behavioral changes with monoamine oxidase B inhibitor. Arch. Gen. Psychiatry 44:427–433, 1987.

    Article  PubMed  CAS  Google Scholar 

  • Thal L.J, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, Pettegrew JW, Pfeiffer E, Raskind MA, Sano M, Tuszynski MH, Woolson RF:A one year multicneter placebo controlled study of acetyl-L-carnitine in patients with Alzheimer’s disease. Neurology, 1996 (in press).

    Google Scholar 

  • Tucek S, Dolezal V. Negative effects of tacrine (tetrahydroaminoacridine) and methoxytacrine on the metabolism of acetylcholine in brain slices incubated under conditions stimulating neurotransmitter release. J. Neurochem. 56:1216–1221, 1991.

    Article  PubMed  CAS  Google Scholar 

  • Tuszynski MH, Sang H, Yoshida K, Gage FH. Recombination human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann. Neurol. 30:625–363, 1991.

    Article  PubMed  CAS  Google Scholar 

  • Vasar R, Harro J, Lang A et al: Anti-exploratory effects of N-methyl-D-aspartate in elevated pis-maze. Involvement of NMDA and CCK receptors. Eur. Neuropsychopharmacol. 3: 63–73, 1993.

    Article  PubMed  CAS  Google Scholar 

  • Vecchi GP, Chiari G, Cipolli C, Cortelloni C. Acetyl-l-carnitine treatment of mental impairment in the elderly: evidence from a multicentre study. Arch. Gerontol. Geriatr. 10 (suppl. 2): 159–168, 1991.

    Google Scholar 

  • Volicer L, Crino PB. Involvement of free radicals in dementia of the ALzheimer’s type hypothesis. Neurobiol. Aging 11:567–571, 1990.

    Article  PubMed  CAS  Google Scholar 

  • Warburton DM, Rusted JM. Cholinergic control of cognitive resources. Neuropsychobiology 28: 43–46, 1993.

    Article  PubMed  CAS  Google Scholar 

  • Weiss JH, Choi DW. Dihydropyridines attenuate slow excitatory amino acid neurotoxicity. In: Nimodipine, pharmacological and clinical studies in cerebral ischemia, Scriabine et al. (eds.) Springer Verlag, Berlin, pp. 57–63, 1991.

    Google Scholar 

  • Whitehouse PJ, Vale WW, Zweig RM, et al. Reduction in corticotropin releasing factor-like immunoreativity in cerebral cortex in Alzheimer’s disease, Parkinson’s disease and progressive sopranuclear palsy. Neurology 37:905–909, 1987.

    Article  PubMed  CAS  Google Scholar 

  • Whittemore SR, Sciger A. The expression, localization and functional significance of beta-nerve growth factor in the central nervous system. Brain Res. Rev. 12:439–464, 1987.

    Article  CAS  Google Scholar 

  • Wilcock GK, Surmon DJ, Scott M et al.: An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer’s disease. Age and Aging 22: 316–324, 1993.

    Article  CAS  Google Scholar 

  • Yan S-D, Chen X, Schmidt A-M, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA 91: 7787–7791, 1994.

    Article  PubMed  CAS  Google Scholar 

  • Yesavage J. Ergoloid mesylates (Hydergine). In: Alzheimer’s disease: treatment and long-term management. Cummings & Miller (eds.) M. Dekker, New York, pp. 45-52, 1990.

    Google Scholar 

  • Zeevalk GD, Nicklas WJ. Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. J. Pharmacol. Exp. Then 253: 1285–1292, 1991.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sezione di Gerontologia e Geriatria Dipartimento di Medicina Clinica, Patologia e Farmacologia, Università degli Studi di Perugia, Italy

    P. Mecocci, M. C. Polidori, A. Cherubini & U. Senin

Authors
  1. P. Mecocci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. C. Polidori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Cherubini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Senin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Palermo, Palermo, Italy

    Mario Barbagallo  & Giuseppe Licata  & 

  2. School of Medicine, Wayne State University, Detroit, Michigan, USA

    James R. Sowers

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mecocci, P., Polidori, M.C., Cherubini, A., Senin, U. (1998). Therapy of Alzheimer’s Dementia. In: Barbagallo, M., Licata, G., Sowers, J.R. (eds) Recent Advances in Geriatrics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1483-5_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4899-1483-5_21

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4899-1485-9

  • Online ISBN: 978-1-4899-1483-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation